Immune response and the lymphatic system are central to cardiac repair after a heart attack, according to a study from Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg Cardiovascular Research Institute.
May 25, 2022
New Research Reveals How the Heart Repairs After a Heart Attack
May 25, 2022 — Immune response and the lymphatic system are central to cardiac repair after a heart attack, according…
Read More
A section of a normal healthy heart (left) and three locations in a heart from a patient with arrhythmogenic cardiomyopathy. There are a lot more fat cells (large while spheres) in the diseased heart. Cardiomyocytes in the composite region often show signs of degeneration, as well as enhanced ZBTB11 expression
May 25, 2022
New Gene Identified in Arrhythmogenic Cardiomyopathy
May 25, 2022 — Researchers from the group of  Eva van Rooij used advanced sequencing technology to better understand…
Read More
The ŌNŌ is intended to simplify bailout procedures in the expanding world of structural heart disease interventions
May 25, 2022
ŌNŌCOR Receives FDA Clearance for Novel Endovascular Retrieval Technology
May 25, 2022 — ŌNŌCOR LLC, a leader in endovascular safety technology, today announced it has received 510(k) U.S. Food…
Read More
Thomas E. MacGillivray, MD
May 25, 2022
Thomas E. MacGillivray Named Chair of Cardiac Surgery for MedStar Heart & Vascular Institute
May 25, 2022 — MedStar Heart & Vascular Institute announced that Thomas E. MacGillivray, MD, has been named…
Read More
Amarin Corporation plc announced that research on the potential population health impact and cost-effectiveness of VASCEPA (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022
May 24, 2022
Research Presented at AHA's QCOR Scientific Sessions Indicate Potential for Vascepa to Reduce Major Adverse CV Events
May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost-…
Read More
Continued research into efficacy of ensoETM for RF ablation procedures will support future regulatory efforts for expanded indications
May 24, 2022
First Patients Enrolled in IMPACT II Study
May 24, 2022 — Attune Medical, a pioneering medical device company with a technology platform based on temperature…
Read More
The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has initiated a voluntary nationwide recall of a single lot of Anagrelide Capsules, USP 0.5 mg (Lot number GD01090), to the consumer level in the United States.
May 24, 2022
Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules
May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has…
Read More
Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening disease
May 24, 2022
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
May 24, 2022 — Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S…
Read More
A specific protein in blood vessel cells plays a major role in the development of vascular and cardiovascular diseases: The presence of too many "thromboxane A2 receptors" hinders the formation of new blood vessels.
May 23, 2022
Researchers Find New Approach to Treating Cardiovascular Diseases
May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and…
Read More
New data from a study of more than 100 million hospitalizations using machine learning augmentation was presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions.
May 23, 2022
Nationwide Study of 100 Million Hospitalizations Finds Percutaneous Coronary Intervention is Safe for Cardio-oncology Patients
May 23, 2022 — New data from a study of more than 100 million hospitalizations using machine learning augmentation was…
Read More
Percutaneous coronary interventions remain below pre-pandemic levels
May 23, 2022
Nationwide Study Finds Significant Decline in Treatment for Heart Attacks During Pandemic
May 23, 2022 — New findings from the Ascension Health System’s internal National Cardiovascular Data Registry (NCDR)…
Read More
Nationwide study points to implicit bias in treatment of cardiovascular disease for non-Hispanic Black patients and highlights need for equity
May 23, 2022
Racial Disparities Seen in Treatment for Patients with Acute Coronary Syndrome and History of Cocaine Use
May 23, 2022 — Insights from a National Inpatient Sample Database examining race and the rates of cardiac…
Read More
Findings underscore need to examine social factors that impact healthcare outcomes for most vulnerable
May 20, 2022
New Study Finds Low-income Patients at Higher Risk of Death After Heart Attack
May 20, 2022 — Results from a retrospective analysis reveal significantly higher mortality rates for low-income…
Read More
First study to compare safety and eficacy of clopidogrel and aspirin monotherapy beyond 12 months in high-risk PCI population
May 20, 2022
Long-term Use of Clopidogrel Monotherapy Associated with Lower Patient Risk Compared to Aspirin Motherapy
May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin…
Read More
Multi-center study explores new treatment for heart failure patients with preserved and reduced ejection fraction
May 20, 2022
No-implant Interatrial Shunt Device to Treat Heart Failure Patients Reveals Promising Multi-center Clinical Data
May 20, 2022 — Results from early clinical evaluation of the Alleviant System to treat heart failure patients with…
Read More
New Analysis Shows the Evolution of Intervention Techniques in Chronic Total Occlusion Patients
May 20, 2022
International Chronic Total Occlusion Percutaneous Coronary Intervention Registry Finds Increasing Procedural Success
May 20, 2022 — A new analysis of PROGRESS-CTO (PROspective Global REgiStry for the Study of Chronic Total Occlusion…
Read More
Three years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at SCAI22.
May 20, 2022
New Longterm Data of Paclitaxel Devices Continues to Show No Increased Mortality Compared to Non-drug Coated Devices
May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-…
Read More
Abbott TriClip G4 device
May 20, 2022
New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies
May 20, 2022 — Abbott announced two late-breaking data presentations highlighting both TriClip, a first-of-its kind…
Read More
The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function. 
May 19, 2022
First Intermediate to Long-term Study of the Harmony Transcatheter Pulmonary Valve System Validates Safety and Efficacy
May 19, 2022 — A study of 1-year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV)…
Read More
First multi-center, randomized controlled study provides the largest long-term evidence for the treatment of heavily calcified femoropopliteal lesions
May 19, 2022
Disrupt PAD III Trial Demonstrates Safety and Effectiveness of Intravascular Lithotripsy for Peripheral Artery Calcification
May 19, 2022 — One year outcomes from the Disrupt PAD III Trial comparing intravascular lithotripsy (IVL) with a drug-…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now